Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer … Read more
Bioatla Inc (BCAB) - Total Assets
Latest total assets as of September 2025: $15.91 Million USD
Based on the latest financial reports, Bioatla Inc (BCAB) holds total assets worth $15.91 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioatla Inc - Total Assets Trend (2018–2024)
This chart illustrates how Bioatla Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bioatla Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Bioatla Inc's total assets of $15.91 Million consist of 97.7% current assets and 2.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Bioatla Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioatla Inc's current assets represent 97.7% of total assets in 2024, an increase from 76.1% in 2018.
- Cash Position: Cash and equivalents constituted 93.6% of total assets in 2024, up from 65.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bioatla Inc Competitors by Total Assets
Key competitors of Bioatla Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Bioatla Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bioatla Inc generates 0.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bioatla Inc is currently not profitable relative to its asset base.
Bioatla Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.54 | 3.11 | 7.46 |
| Quick Ratio | 0.54 | 3.11 | 7.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.31 Million | $ 41.10 Million | $ 208.42 Million |
Bioatla Inc - Advanced Valuation Insights
This section examines the relationship between Bioatla Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -56.2% |
| Total Assets | $52.42 Million |
| Market Capitalization | $7.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioatla Inc's assets below their book value (0.15 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bioatla Inc's assets decreased by 56.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bioatla Inc (2018–2024)
The table below shows the annual total assets of Bioatla Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $52.42 Million | -56.19% |
| 2023-12-31 | $119.66 Million | -46.99% |
| 2022-12-31 | $225.74 Million | -11.27% |
| 2021-12-31 | $254.42 Million | +3.87% |
| 2020-12-31 | $244.94 Million | +2523.58% |
| 2019-12-31 | $9.34 Million | -43.88% |
| 2018-12-31 | $16.64 Million | -- |